What WEST PHARMACEUTICAL SERVICES INC's SEC filings said

10-Q for 2026Q3, filed 29 Oct 2026, and 1 8-K since. Each line is something a filing stated, ranked by score and linked to its source.

Ranked highest

Capital Expenditure Guidance73 · importance in its document · 8-K exhibit · 29 Oct 2026
First-nine-month capital expenditures were $125.0 million, down from $209.8 million in the same 2025 period. Full-year 2026 capital spending guidance was reduced to $215 million–$220 million from the prior range of $250 million–$275…
Operating Profit and Margins69 · importance in its document · 10-Q · 2026Q3
Consolidated GAAP operating profit increased 59.5% to $267.4 million in the third quarter of 2026 and 45.6% to $623.6 million in the first nine months; reported operating margins were 30.6% and 24.1%, respectively. Adjusted operating…
Share Repurchase Program69 · importance in its document · 8-K exhibit · 29 Oct 2026
West repurchased $231 million of stock in the third quarter, bringing year-to-date repurchases to $685 million. Cash-flow disclosures report $685.3 million of shares purchased under repurchase programs in the first nine months of 2026,…
Revenue Performance and Mix60 · importance in its document · 10-Q · 2026Q3
For the three months ended September 30, 2026, consolidated organic net sales grew 11.9% year over year, with volume and mix contributing $58.3 million and price increases contributing $33.6 million. Proprietary Products organic net sales…
Guidance raised60 · rule score among filings · 8-K Item 2.02 · 29 Oct 2026
West Reports Third-Quarter 2026 Results Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance Exton, PA, October 29, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable…

Ranked by score, 0–100. A topic read from a document carries its importance within that document; an 8-K event carries the rule score that ranks a filing among filings. Neither is about the share price, and the two scales are named on each row because they are not the same measure.

Latest report: 10-Q · 2026Q3 filed 29 Oct 2026

Full report · Filing on EDGAR

Operating Profit and MarginsImportance 69
Consolidated GAAP operating profit increased 59.5% to $267.4 million in the third quarter of 2026 and 45.6% to $623.6 million in the first nine months; reported operating margins were 30.6% and 24.1%, respectively.…
Revenue Performance and MixImportance 60
For the three months ended September 30, 2026, consolidated organic net sales grew 11.9% year over year, with volume and mix contributing $58.3 million and price increases contributing $33.6 million. Proprietary…
Acquisition / Partnership / DivestitureImportance 59
On July 1, 2026, West sold its SmartDose® 3.5mL On-Body Delivery System product line to AbbVie, reducing third-quarter sales by $18.0 million compared with the prior-year quarter. The sale of the assets generated a…
Operating Cash Flow TrendsImportance 54
Net cash provided by operating activities decreased $100.3 million, from $503.7 million to $403.4 million, for the nine months ended September 30, 2026. The decline was primarily driven by increased customer accounts…
Liquidity and Debt PositionImportance 51
At September 30, 2026, West held $464.1 million in cash and cash equivalents and had total debt of $202.9 million, essentially unchanged from $202.8 million at December 31, 2025. The company had no borrowings under its…
Gross Margin DriversImportance 48
Consolidated gross profit for the third quarter of 2026 increased $53.1 million, or 18.0%, to $347.4 million, and gross margin expanded 3.1 percentage points to 39.7%; nine-month gross profit rose $172.9 million, or…
Interest Rate EnvironmentImportance 45
For the nine months ended September 30, 2026, net interest expense increased $7.6 million year over year, from $0.7 million to $8.3 million. The filing attributes the increase primarily to lower capitalized interest,…
Operating Expense TrendsImportance 41
Consolidated SG&A increased 9.9% to $112.9 million in the third quarter of 2026 and 15.1% to $330.0 million in the first nine months, while SG&A as a share of sales was 12.9% and 12.7%, respectively. Nine-month…
Income Tax Rate ChangesImportance 39
The effective tax rate for the three months ended September 30, 2026 was 21.7%, compared with 19.8% in the prior-year quarter, on income tax expense of $58.0 million versus $34.0 million. The quarterly rate increase…
Share Repurchase ProgramImportance 33
West repurchased 2,424,121 shares of common stock during the nine months ended September 30, 2026, for $685.3 million, at an average price of $282.68 per share. The company identified share repurchases as a primary…

Capital spending check: Capital spending cut sharply (Flagged, rule score 50).

8-K filings last 12 months

Guidance raised29 Oct 2026 · 8-K Item 2.02 · Flagged · rule score 60
“West Reports Third-Quarter 2026 Results Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance Exton, PA, October 29, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable…”
Read from the attached exhibit: Capital Expenditure Guidance · Share Repurchase Program · Income Tax Rate Changes
New debt26 Oct 2026 · 8-K Item 2.03 · Routine · rule score 35
Results (release not read)23 Jul 2026 · 8-K Item 2.02 · Routine · rule score 20
Management change (filing not read)1 Jun 2026 · 8-K Item 5.02 · Routine · rule score 20
Results (release not read)23 Apr 2026 · 8-K Item 2.02 · Routine · rule score 20
CEO exit, planned succession9 Mar 2026 · 8-K Item 5.02 · Flagged · rule score 60
“Today, March 9, 2026 , West Pharmaceutical Services, Inc. (the “Company”) announced that Mr. Eric M. Green, President, Chief Executive Officer and Chair of the Board of Directors (the “Board) of the Company, informed the Board on March 6,…”
Results (release not read)12 Feb 2026 · 8-K Item 2.02 · Routine · rule score 20

Topics are read from the text of the 10-K, 10-Q or the exhibit attached to an 8-K, each linked to the passage it came from. 8-K events are labelled by fixed rules from the item codes and the filing text — the same rules for every company and every year. The Full Picture merges these with earnings calls and news.